Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App
Zacks Investment Research | Feb 04, 2018 09:50PM ET
The fourth-quarter earnings season has taken center stage, with 251 S&P 500 members having reported their numbers. The season has turned out to be favorable so far, especially on the revenue front. A sturdy revenue momentum was witnessed in the season, above-average proportion of positive surprises along with favorable revisions trend for the present and the upcoming quarters.
Per the latest Becton, Dickinson and Company Quote
AmerisourceBergen Corporation (NYSE:ABC) )
AmerisourceBergen is scheduled to report first-quarter fiscal 2018 results before the market opens.
Notably, the Zacks Consensus Estimate for first-quarter revenues is pegged at $40.37 billion, up 5.8% year over year. The Zacks Consensus Estimate for first-quarter earnings is $1.35, down 0.7% on a year-over-year basis.
This quarter, AmerisourceBergen is expected to show steady growth in the pharmaceutical distribution segment, a significant contributor to revenues. The Zacks Consensus Estimate for the Pharmaceutical Distribution segment is at $38.74 billion for the quarter under review, up almost 5.9% from the year-ago quarter (read more: AmerisourceBergen Corporation (Holding Co) Quote
Laboratory Corporation of America Holdings (NYSE:LH) )
Laboratory Corporation of America Holdings, also known as LabCorp, is slated to report fourth-quarter 2017 results, before the market opens.
The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $2.71 billion, up 11.5% year over year. The Zacks Consensus Estimate for fourth-quarter earnings is $2.37, up 10.2% on a year-over-year basis.
After several quarters of dismal performance, Covance Drug Development witnessed revenue growth in the third quarter, courtesy of strong organic growth, favorable foreign currency translation and the Chiltern acquisition.
Chiltern has added high-complementary capabilities to LabCorp’s offerings, including scale expansion in Asia Pacific, wider reach in the fast-growing emerging and mid-tier biopharma customer segment and expertise in oncology drug development. All these factors are likely to drive LabCorp’s Covance Drug Development top line in the yet-to-be reported quarter. (Read More: Laboratory Corporation of America Holdings Quote
Get The News You Want
Cerner Corporation (NASDAQ:CERN) )
Cerner is set to report fourth-quarter 2017 results, after the market closes.
The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $1.33 billion, up 5.5% year over year. The Zacks Consensus Estimate for fourth-quarter earnings is 61 cents per share, flat on a year-over-year basis.
The company is expected to show steady growth in System Sales — one of the major revenue components. While this is expected to drive fourth-quarter results, an expected improvement in revenues in other segments will help the company generate solid results. The Zacks Consensus Estimate for System Sales revenues is pegged at $357 million, up 10.2% from last quarter. With growth in Cerner’s licensed software and subscriptions, Cerner is expected to witness strong performance in the segment (read more: Cerner Corporation Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.